Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder

Authors

Manish Agrawal, MD; Ezekiel Emanuel, MD, PhD; Brian Richards, PhD; William Richards, PhD; Kim Roddy, MBA; Paul Thambi, MD

Originally published in JAMA Oncology as Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder.

This nonrandomized controlled trial used a 1-to-1 therapist-to-patient ratio to administer psilocybin to groups of patients with cancer who were diagnosed with major depression disorder to create a scalable, rapidly effective depression treatment.

About 15% of patients with cancer experience major depression, which is associated with lower treatment adherence and reduced quality of life.1,2 Yet, oncologists often feel inadequate to address mental health issues, and many treatments have limited success in treating depression.3

Published Date: April 13, 2023